Edrecolomab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Edrecolomab
Accession Number
DB13375
Type
Biotech
Groups
Experimental, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
0KYI9U9FSJ
CAS number
156586-89-9

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Edrecolomab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Edrecolomab.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Edrecolomab.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Edrecolomab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Edrecolomab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Edrecolomab is combined with Belimumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Edrecolomab.Approved, Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Edrecolomab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Edrecolomab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Edrecolomab.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Edrecolomab.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Edrecolomab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Edrecolomab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Edrecolomab.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Edrecolomab.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Edrecolomab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Edrecolomab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Edrecolomab.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Edrecolomab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Edrecolomab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Edrecolomab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Edrecolomab.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Edrecolomab.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Edrecolomab.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Edrecolomab.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Edrecolomab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Edrecolomab.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Edrecolomab.Experimental
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Edrecolomab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Edrecolomab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Edrecolomab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Edrecolomab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Edrecolomab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Edrecolomab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Edrecolomab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Edrecolomab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Edrecolomab.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Edrecolomab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Edrecolomab.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
L01XC01 — Edrecolomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentColorectal Cancers1
3CompletedTreatmentMucinous Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Colon / Stage IIA Colon Cancer / Stage IIB Colon Cancer / Stage IIC Colon Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:40 / Updated on January 05, 2018 13:27